Future of COPD Care: 5 Treatments Medicare May Cover by 2026

If you manage Chronic Obstructive Pulmonary Disease (COPD), staying informed about new treatments is essential. You likely clicked here wondering about the future of care and how Medicare coverage might adapt. This guide explores five promising COPD treatments and procedures that are being discussed for potential Medicare coverage or pricing changes by 2026, giving you a clear look at what may be on the horizon.

Why 2026 is a Key Year for Medicare Coverage

Before we look at specific treatments, it’s important to understand why 2026 is a significant year for Medicare. The Inflation Reduction Act of 2022 gave Medicare the power to negotiate prices for certain high-cost prescription drugs for the first time. The first round of these newly negotiated prices will take effect in 2026.

This means that some expensive, brand-name COPD medications that are currently on the market could become more affordable and accessible for beneficiaries. Additionally, new medical devices and therapies are constantly being developed and reviewed by the Food and Drug Administration (FDA). When these get approved, the Centers for Medicare & Medicaid Services (CMS) must then decide if they are “reasonable and necessary” for Medicare coverage. This combination of drug price negotiations and new technology approvals makes the coming years a critical time for COPD care.

Here are five treatments and therapies that are part of this evolving landscape.

1. Biologic Therapies (Monoclonal Antibodies)

Biologic drugs are a newer class of medication designed to target specific inflammatory pathways in the body. For some COPD patients, particularly those whose condition has an inflammatory component similar to asthma (often called eosinophilic-phenotype), these treatments can be very effective at reducing flare-ups, also known as exacerbations.

How it Works: Unlike general anti-inflammatory drugs like steroids, biologics target precise molecules that cause lung inflammation. For example, Dupilumab (brand name Dupixent) blocks two key proteins involved in inflammation.
Current Status: In June 2024, the FDA approved Dupixent as an add-on maintenance treatment for adults with uncontrolled COPD associated with eosinophilic-phenotype. This is a major development.
Potential Medicare Impact by 2026: Because Dupixent is a high-cost specialty drug administered by injection, it falls under Medicare Part B. With its new approval for COPD, CMS will be establishing clear coverage guidelines. Its high price also makes it a potential candidate for future drug price negotiations, which could influence its accessibility for Medicare patients by 2026 and beyond.

2. Bronchoscopic Lung Volume Reduction (BLVR)

For patients with severe emphysema, a form of COPD, certain parts of the lungs become badly damaged and lose their elasticity. These damaged areas can trap air and expand, pressing on healthier parts of the lung and making it difficult to breathe. Bronchoscopic Lung Volume Reduction (BLVR) is a minimally invasive procedure that offers an alternative to major surgery.

How it Works: A doctor uses a bronchoscope to place tiny, one-way valves in the airways leading to the most damaged parts of the lung. A popular example is the Zephyr Valve. These valves allow trapped air to escape but prevent new air from entering, which helps the damaged lobe shrink. This gives the healthier parts of the lung more room to function.
Current Status: BLVR using endobronchial valves like Zephyr is FDA-approved and already has Medicare coverage for patients who meet very specific criteria.
Potential Medicare Impact by 2026: While already covered, the guidelines and criteria for patient selection are continually being refined as more data becomes available. By 2026, we may see an expansion or clarification of the coverage criteria, potentially making this procedure available to a wider group of eligible patients as its long-term benefits become even more established.

3. Targeted Lung Denervation (TLD)

Targeted Lung Denervation is an innovative therapy currently in clinical trials that aims to provide long-lasting relief from airway constriction. It focuses on the nerves around the airways that contribute to COPD symptoms.

How it Works: This is a one-time bronchoscopic procedure that uses radiofrequency energy to disrupt the overactive nerve signals along the outside of the airways. This process, called denervation, relaxes the airway muscles, making it easier to breathe. The goal is to reduce the risk of exacerbations.
Current Status: TLD is still investigational and not yet FDA-approved for general use. It is undergoing extensive clinical trials to prove its safety and effectiveness.
Potential Medicare Impact by 2026: If the clinical trials yield positive results and the therapy receives FDA approval in the next couple of years, CMS would then need to conduct a thorough review to determine if it will be covered by Medicare. Given its potential to reduce hospitalizations, it is a significant therapy being watched closely, and a coverage decision could be made around the 2026 timeframe.

4. Novel Dual-Mechanism Inhalers

While combination inhalers are a staple of COPD treatment, pharmaceutical research continues to produce more advanced options. A new class of drugs is emerging that combines bronchodilation (opening the airways) and anti-inflammatory effects in a single molecule.

How it Works: A leading example is Ensifentrine. It is a first-in-class drug known as a “dual-inhibitor.” It works by inhibiting two enzymes, PDE3 and PDE4. This dual action both relaxes the airway muscles and reduces inflammation in the lungs.
Current Status: Ensifentrine has completed successful clinical trials and is currently under review by the FDA, with a decision expected. If approved, it would offer a new type of maintenance therapy for COPD patients.
Potential Medicare Impact by 2026: As a new brand-name prescription drug, an approved Ensifentrine would be covered under Medicare Part D. Its initial cost will be a key factor. If it proves to be a high-expenditure drug for Medicare, it could become a target for price negotiation in the years following 2026, potentially improving its affordability for seniors on fixed incomes.

5. Advanced Pulmonary Rehabilitation Programs

Pulmonary rehabilitation is a cornerstone of COPD management, combining exercise, education, and support. While traditional programs are covered by Medicare, new approaches, including virtual and home-based models, are gaining traction.

How it Works: These programs use digital health technology, such as remote monitoring devices, video conferencing with therapists, and online educational modules, to deliver rehabilitation services directly to a patient’s home. This overcomes transportation and mobility barriers.
Current Status: Medicare coverage for telehealth and remote services expanded greatly during the COVID-19 public health emergency. While some of those provisions have been made permanent, specific guidelines for comprehensive, home-based pulmonary rehab are still evolving.
Potential Medicare Impact by 2026: There is a strong push from patient advocacy groups and healthcare providers to establish permanent, widespread Medicare coverage for virtual pulmonary rehabilitation. Given the proven benefits of rehab in reducing hospital readmissions, CMS is actively evaluating these models. By 2026, we could see formal and permanent coverage policies that make these convenient and effective programs accessible to all Medicare beneficiaries with COPD.

Frequently Asked Questions

How do I know if my current COPD medication is covered by Medicare? The best way is to check your specific Medicare Part D (prescription drug) plan’s formulary, which is the list of covered drugs. You can find this on your plan’s website or by calling their customer service number.

What is the difference between Medicare Part B and Part D for COPD treatments? Generally, Medicare Part D covers prescription drugs you get from a pharmacy, like inhalers and pills. Medicare Part B covers medical services and supplies, which can include drugs administered in a doctor’s office (like some biologics), oxygen equipment, and pulmonary rehabilitation services.

Should I talk to my doctor about these future treatments? Yes, absolutely. Your doctor is your most important partner in managing your COPD. They can tell you if you might be a candidate for any of these therapies if and when they become available and help you navigate the best treatment plan based on your specific health needs.